Viela Bio (Viela Bio) Days Sales Outstanding : 38.57 (As of Dec. 2020)

View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Days Sales Outstanding?

Viela Bio's average Accounts Receivable for the three months ended in Dec. 2020 was $3.95 Mil. Viela Bio's Revenue for the three months ended in Dec. 2020 was $9.34 Mil. Hence, Viela Bio's Days Sales Outstanding for the three months ended in Dec. 2020 was 38.57.

The historical rank and industry rank for Viela Bio's Days Sales Outstanding or its related term are showing as below:

VIE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 219 Med: 386.61 Max: 554.22
Current: 395.66

During the past 3 years, Viela Bio's highest Days Sales Outstanding was 554.22. The lowest was 219.00. And the median was 386.61.

VIE's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 73.34 vs VIE: 395.66

Viela Bio's Days Sales Outstanding declined from Dec. 2019 (53.42) to Dec. 2020 (38.57).

Viela Bio Days Sales Outstanding Historical Data

The historical data trend for Viela Bio's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Days Sales Outstanding Chart

Viela Bio Annual Data

Trend

Dec18

Dec19

Dec20

Days Sales Outstanding

219.00

554.22

Viela Bio Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Days Sales Outstanding	Get a 7-Day Free Trial					53.42	-	-	98.78	38.57

Competitive Comparison of Viela Bio's Days Sales Outstanding

For the Biotechnology subindustry, Viela Bio's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viela Bio's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viela Bio's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Viela Bio's Days Sales Outstanding falls into.

Viela Bio Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Viela Bio's Days Sales Outstanding for the fiscal year that ended in Dec. 2020 is calculated as

	Days Sales Outstanding (A: Dec. 2020 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2019 )	+	Accounts Receivable (A: Dec. 2020 ))	/	count )	/	Revenue (A: Dec. 2020 )	*	Days in Period
=	( (30	+	5.385)	/	2 )	/	11.652	*	365
=	17.6925					/	11.652	*	365
=	554.22

Viela Bio's Days Sales Outstanding for the quarter that ended in Dec. 2020 is calculated as:

	Days Sales Outstanding (Q: Dec. 2020 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2020 )	+	Accounts Receivable (A: Dec. 2020 ))	/	count )	/	Revenue (A: Dec. 2020 )	*	Days in Period
=	( (2.507	+	5.385)	/	2 )	/	9.336	*	365 / 4
=	3.946					/	9.336	*	365 / 4
=	38.57

Viela Bio (NAS:VIE) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Viela Bio Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Viela Bio's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Viela Bio (Viela Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878

Website

https://www.vielabio.com

Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.

Executives

Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu	director	10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd	10 percent owner	SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund	10 percent owner	CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao	director, officer: Chief Executive Officer	10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz	officer: VP, Head of Commercial	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878